Don’t let winter ailments slow you down. Discover how understanding your symptoms can lead to powerful relief while embracing ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

A prominent paediatrician on Sunday urged people to take more precautions against a common virus known as RSV, saying cases ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

A new study shows that a vaccine against respiratory syncytial virus is associated with a 29% reduction in dementia risk in ...